Sanofi

Vendu! Weeks after Sanofi cuts ties to Alnylam, the pharma giant offloads $842M of its stock
Vendu! Weeks after Sanofi cuts ties to Alnylam, the pharma giant offloads $842M of its stock
Endpoints
Sanofi
Alnylam
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Regeneron
Sanofi
Praluent
FDA
Heron Therapeutics
HTX-011
Nabiva
Orchard Therapeutics
Akari Therapeutics
Aldeyra Therapeutics
BioTime
Audentes Therapeutics
Adaptimmune
GW Pharma
Ionis
Biogen
Ovid Therapeutics
TransMedics
IPOs
Trevi Therapeutics
Flag link:
Praluent's lower list price isn't yielding better sales yet
Praluent's lower list price isn't yielding better sales yet
Biopharma Dive
Sanofi
Regeneron
Praluent
drug pricing
Flag link:
U.S. FDA approves expanded label for Regeneron/Sanofi's cholesterol drug
U.S. FDA approves expanded label for Regeneron/Sanofi's cholesterol drug
Yahoo/Reuters
Regeneron
Sanofi
Praluent
MACE
FDA
Flag link:
Sanofi's Eloctate, a Bioverativ buyout centerpiece, suffers on Roche's Hemlibra launch
Sanofi's Eloctate, a Bioverativ buyout centerpiece, suffers on Roche's Hemlibra launch
Fierce Pharma
Sanofi
Bioverativ
M&A
diabetes
Eloctate
Roche
Hemlibra
Flag link:
Sanofi (SNY) Q1 Earnings Top, Genzyme & Vaccines Drive Sales
Sanofi (SNY) Q1 Earnings Top, Genzyme & Vaccines Drive Sales
Yahoo/Zacks.com
Sanofi
earnings
Flag link:
Sanofi leases its soon-to-be-former Genzyme HQ to Bluebird Bio—at a profit
Sanofi leases its soon-to-be-former Genzyme HQ to Bluebird Bio—at a profit
Fierce Pharma
Sanofi
Bluebird Bio
Kendall Square
Boston
Flag link:
Before House hearing, Sanofi cuts insulin prices for some patients
Before House hearing, Sanofi cuts insulin prices for some patients
Stat
Sanofi
insulin
diabetes
drug pricing
Flag link:
The top 15 pharma companies by 2018 revenue
The top 15 pharma companies by 2018 revenue
Fierce Pharma
JNJ
Roche
Pfizer
Novartis
Merck
GSK
Sanofi
AbbVie
Bayer
Eli Lilly
Amgen
Bristol-Myers Squibb
Gilead Sciences
Teva Pharmaceutical
AstraZeneca
Flag link:
Sanofi plans sales layoffs—again—in primary care, diabetes
Sanofi plans sales layoffs—again—in primary care, diabetes
Fierce Pharma
Sanofi
layoffs
primary care
diabetes
drug reps
Flag link:
Sanofi's latest digital foray starts with OTC home delivery in Latin America
Sanofi's latest digital foray starts with OTC home delivery in Latin America
Fierce Pharma
Sanofi
Rappi
digital health
digital pharma
Latin America
Flag link:
Sanofi may airlift medicines into UK after Brexit
Sanofi may airlift medicines into UK after Brexit
Pharmaforum
Sanofi
UK
Europe
Brexit
vaccines
flu vaccines
Flag link:
What's Next for Lexicon Pharmaceuticals?
What's Next for Lexicon Pharmaceuticals?
Motley Fool
Lexicon Pharmaceuticals
sotagliflozin
Zynquista
Sanofi
diabetes
Flag link:
Sanofi, Lexicon get complete response letter for Zynquista
Sanofi, Lexicon get complete response letter for Zynquista
BioCentury
Sanofi
Zynquista
Lexicon Pharmaceuticals
type 1 diabetes
FDA
Flag link:
Exclusive: Sanofi says working on CEO succession plan
Exclusive: Sanofi says working on CEO succession plan
Yahoo/Reuters
Sanofi
Pharma CEOs
Olivier Brandicourt
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
Yahoo/Benzinga
Roche
SAGE Therapeutics
Ligand Pharmaceuticals
brexanolone
Tecentriq
Jazz Pharmaceuticals
JZP-110
Sanofi
Lexicon Pharmaceuticals
Zynquista
PhaseBio
AstraZeneca
Amarin
Leap Therapeutics
Strongbridge
Flag link:
Merck limits orders for bladder cancer drug as demand outstrips supply
Merck limits orders for bladder cancer drug as demand outstrips supply
Fierce Pharma
Merck
bladder cancer
TICE BCG
Sanofi
Flag link:
FDA approves Dupixent for atopic dermatitis in adolescents
FDA approves Dupixent for atopic dermatitis in adolescents
BioCentury
Dupixent
Regeneron
Sanofi
FDA
atopic dermatitis
Flag link:
Two big pharma execs share the same challenges, but compensation? They’re not even close
Two big pharma execs share the same challenges, but compensation? They’re not even close
Endpoints
Pharma CEOs
executive pay
AbbVie
Sanofi
Richard Gonzalez
Olivier Brandicourt
Flag link:
FDA panel does not back broad reach of Sanofi's dengue vaccine
FDA panel does not back broad reach of Sanofi's dengue vaccine
BioCentury
Sanofi
dengue
Dengvaxia
FDA
advisory panels
Flag link:

Pages